Worth reading
55In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
0
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Series 7 and Series 8 stock acquisition rights issued through a third-party allotment, with the option to elect an exercise-price adjustment clause, and Series 9 stock acquisition rights with a fixed exercise price
発行済株式総数
Exercise ratio during the relevant month: Series 7 0.00%, Series 8 0.00%, Series 9 0.00%. Exercise ratio subject to exercise restrictions: 0.00%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Series 7: ¥3,050. Series 8: ¥3,500. Series 9: ¥4,000. Series 7 and Series 8 include the right to convert to stock acquisition rights with an adjustable exercise price; Series 9 has a fixed exercise price. Lower limit of adjustment: Not disclosed
Number of Stock Acquisition Rights
Series 7: total issued, 1,500 units; unexercised balance at the end of the relevant month, 1,465 units. Series 8: total issued, 1,500 units; unexercised balance at the end of the relevant month, 1,500 units. Series 9: total issued, 750 units; unexercised balance at the end of the relevant month, 750 units
Payment date
31 July 2026 (stated as the issue date)
Procedures under the Corporate Code of Conduct
Details of compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc.
Most recent equity financing
Timing 31 July 2026 / Type Issuance of Series 7, Series 8 and Series 9 stock acquisition rights through a third-party allotment / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Series 7 and Series 8 stock acquisition rights issued through a third-party allotment, with the option to elect an exercise-price adjustment clause, and Series 9 stock acquisition rights with a fixed exercise price |
| Payment date | 31 July 2026 (stated as the issue date) |
| Dilution Rate | Exercise ratio during the relevant month: Series 7 0.00%, Series 8 0.00%, Series 9 0.00%. Exercise ratio subject to exercise restrictions: 0.00% |
| Total number of issued shares | As of the end of the month preceding the relevant month: 1,521,500 shares (including 264 treasury shares) → Not disclosed |
| Exercise price | Series 7: ¥3,050. Series 8: ¥3,500. Series 9: ¥4,000. Series 7 and Series 8 include the right to convert to stock acquisition rights with an adjustable exercise price; Series 9 has a fixed exercise price. Lower limit of adjustment: Not disclosed |
| Number of Stock Acquisition Rights | Series 7: total issued, 1,500 units; unexercised balance at the end of the relevant month, 1,465 units. Series 8: total issued, 1,500 units; unexercised balance at the end of the relevant month, 1,500 units. Series 9: total issued, 750 units; unexercised balance at the end of the relevant month, 750 units |
| Procedures under the Corporate Code of Conduct | Details of compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc. |
| Most recent equity financing | Timing 31 July 2026 / Type Issuance of Series 7, Series 8 and Series 9 stock acquisition rights through a third-party allotment / Amount Not disclosed |
Items this document does not state (20)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company reported that there were no exercises during the relevant month, but did not state the reason.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.